“GLP-3” shows up in search. It is not a pharmacopeial name. In practice it is an informal nickname for retatrutide (LY3437943) — the synthetic peptide studied as a triple agonist at the glucagon receptor (GCGR), GIP receptor (GIPR), and GLP-1 receptor (GLP-1R) (Coşkun et al., Cell Metabolism, 2022; PMID 35985340).
This page resolves the nickname. Full chemical identity lives on the retatrutide research guide. Lot CoA literacy lives on Quality. Triple vs dual receptor tables live on retatrutide vs tirzepatide.
What is GLP-3?
“GLP-3” is informal search language for multi-receptor / triple-agonist peptides, and in almost every lab-supply and forum use it means retatrutide. It is not an INN, USAN, or FDA proper name. Peer-reviewed discovery work names the molecule LY3437943 and describes triple GCGR / GIPR / GLP-1R agonist activity — not a substance called “GLP-3” (PMID 35985340).
FDA substance records list retatrutide with synonyms including LY3437943 and INN/USAN forms (UNII NOP2Y096GV). UNII listing is not approval.
Is GLP-3 a hormone?
No. There is no established endogenous human hormone named “GLP-3.” GLP-1 and GLP-2 are real glucagon-like peptide hormones with defined receptors. The “3” in slang counts three receptor targets on an engineered agonist, not a third GLP hormone. Primary literature for this molecule uses retatrutide / LY3437943 / triple agonist language (PMID 35985340).
What does GLP-3 RT mean?
“GLP-3 RT,” “GLP3-RT,” and similar strings are community shorthand pairing the “GLP-3” nickname with retatrutide. They point at the same investigational research entity: retatrutide (LY3437943). After the first mention on a page, prefer the INN.
How does the nickname map to the INN?
| Informal search term | Prefer in lab notes / citations |
|---|---|
| GLP-3, GLP3, GLP-3 RT | retatrutide |
| “triple G” / “triple agonist” (informal) | LY3437943 + receptor list (GCGR, GIPR, GLP-1R) |
Mechanism label in the discovery paper: novel triple glucagon, GIP, and GLP-1 receptor agonist (PMID 35985340). Retatrutide remains investigational in peer-reviewed clinical literature (e.g. PMID 37366315); that citation is for status only — not outcomes copy on this page.
What should labs verify on a research-grade lot?
A nickname does not identify a lot. Read Lot, accession, measured HPLC, identity method, laboratory, and dates from the certificate for the size in hand. Match the vial lot to the CoA lot. How to read those fields: Quality & CoA literacy. Do not use another size’s certificate.
Related research pages
- Identity / specs: What is retatrutide?
- Research-grade listing: Retatrutide catalog
- Triple vs dual: Retatrutide vs tirzepatide
- CoA literacy: Quality
Frequently Asked Questions
What is GLP-3?+
Is GLP-3 a hormone?+
What is GLP-3 RT?+
Is GLP-3 the same as retatrutide?+
Is research-grade retatrutide an approved drug product?+
References
- Coşkun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… Cell Metabolism. 2022;34(9):1234-1247.e9. PMID: 35985340.
- FDA Substance Registration System — UNII NOP2Y096GV (retatrutide / LY3437943). https://precision.fda.gov/uniisearch/srs/unii/NOP2Y096GV
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity… N Engl J Med. 2023. PMID: 37366315 — investigational clinical literature cite-only; no outcomes pasted here.